PCVXVaxcyte, Inc.
62.62USD-1.07%Mkt Cap: 9.32B $P/E: —3d ago
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-spari…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap9.32B $
Enterprise Value7.76B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-766.63M $
Revenue/Share—
Last Price62.62 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees507
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.50
PEG—
EV/EBITDA-6.75
EV/Revenue—
P/S—
P/B3.22
EPS (TTM)-7.40
EPS (Forward)-7.22
52W Range
29.8793% of range65.00
52W High65.00 USD
52W Low29.87 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-28.55%
ROA-25.53%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-655.58M $
CapEx (TTM)56.97M $
FCF Margin—
FCF Yield-5.21%
Net Debt-1.37B $
Net Debt/EBITDA1.19
Balance Sheet
Debt/Equity0.04
Current Ratio5.72
Quick Ratio5.48
Book Value/Sh19.05 USD
Cash/Share9.992 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)109.00 USD
Upside (mean)+74.1%
Target Range67.00 USD – 163.00 USD
$67.00+74.1% to mean$163.00
# Analysts9
Ownership
Shares Out.148.81M
Float136.48M
Insiders0.48%
Institutions113.44%
Short Interest
Short Ratio12.8d
Short % Float10.04%
Short % Out.9.99%
Shares Short14.46M
Short (prev mo.)17.47M
Technical
SMA 5055.78 (+12.3%)
SMA 20053.12 (+17.9%)
Beta1.21
S&P 52W Chg18.16%
Avg Vol (30d)918.37K
Avg Vol (10d)930.13K
Technical Indicators
RSI (14)64.7
MACD1.6822
MACD Signal1.1095
MACD Hist.+0.5727
BB Upper63.10 USD
BB Middle57.24 USD
BB Lower51.38 USD
BB Width20.48%
ATR (14)2.392 USD
Vol Ratio (20d)1.20x